Genmab A/S
GMAB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $97,160,078 | $141,716,771 | $192,457,402 | $169,123,215 |
| - Cash | $9,858,000 | $14,867,000 | $9,893,000 | $8,957,000 |
| + Debt | $1,029,000 | $770,000 | $597,000 | $425,000 |
| Enterprise Value | $88,331,078 | $127,619,771 | $183,161,402 | $160,591,215 |
| Revenue | $21,526,000 | $16,474,000 | $14,505,000 | $8,417,000 |
| % Growth | 30.7% | 13.6% | 72.3% | – |
| Gross Profit | $20,541,000 | $16,248,000 | $14,505,000 | $8,417,000 |
| % Margin | 95.4% | 98.6% | 100% | 100% |
| EBITDA | $9,697,000 | $5,947,000 | $7,346,000 | $4,181,000 |
| % Margin | 45% | 36.1% | 50.6% | 49.7% |
| Net Income | $7,844,000 | $4,352,000 | $5,452,000 | $2,957,000 |
| % Margin | 36.4% | 26.4% | 37.6% | 35.1% |
| EPS Diluted | 12.14 | 6.6 | 8.26 | 4.48 |
| % Growth | 83.9% | -20.1% | 84.4% | – |
| Operating Cash Flow | $7,771,000 | $7,380,000 | $3,912,000 | $2,228,000 |
| Capital Expenditures | -$187,000 | -$376,000 | -$317,000 | -$252,000 |
| Free Cash Flow | $7,584,000 | $7,004,000 | $3,595,000 | $1,976,000 |